Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 9 studies | 35% ± 21% | |
adipocyte | 8 studies | 25% ± 10% | |
astrocyte | 8 studies | 32% ± 18% | |
GABAergic neuron | 7 studies | 32% ± 17% | |
oligodendrocyte precursor cell | 7 studies | 31% ± 16% | |
oligodendrocyte | 7 studies | 31% ± 12% | |
endothelial cell | 6 studies | 34% ± 10% | |
interneuron | 6 studies | 43% ± 24% | |
macrophage | 5 studies | 24% ± 6% | |
epithelial cell | 4 studies | 28% ± 12% | |
fibroblast | 4 studies | 25% ± 7% | |
cardiac muscle cell | 3 studies | 31% ± 4% | |
ciliated cell | 3 studies | 24% ± 7% | |
endothelial cell of lymphatic vessel | 3 studies | 24% ± 3% | |
type I pneumocyte | 3 studies | 22% ± 5% | |
type II pneumocyte | 3 studies | 21% ± 4% | |
microglial cell | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1060.36 | 1445 / 1445 | 100% | 16.50 | 183 / 183 |
stomach | 100% | 790.75 | 359 / 359 | 100% | 14.65 | 286 / 286 |
intestine | 100% | 1133.68 | 966 / 966 | 100% | 14.49 | 525 / 527 |
prostate | 100% | 961.72 | 245 / 245 | 100% | 19.95 | 500 / 502 |
breast | 100% | 1012.56 | 459 / 459 | 100% | 19.18 | 1113 / 1118 |
brain | 99% | 854.01 | 2628 / 2642 | 100% | 13.29 | 705 / 705 |
lung | 99% | 835.79 | 575 / 578 | 100% | 14.45 | 1153 / 1155 |
ovary | 100% | 957.69 | 180 / 180 | 99% | 11.49 | 427 / 430 |
thymus | 100% | 894.93 | 653 / 653 | 99% | 12.21 | 599 / 605 |
bladder | 100% | 1047.76 | 21 / 21 | 99% | 13.80 | 499 / 504 |
uterus | 100% | 1085.22 | 170 / 170 | 99% | 15.20 | 453 / 459 |
kidney | 100% | 1010.87 | 89 / 89 | 98% | 11.99 | 882 / 901 |
pancreas | 98% | 457.76 | 323 / 328 | 99% | 12.20 | 176 / 178 |
skin | 100% | 1476.37 | 1809 / 1809 | 95% | 13.12 | 449 / 472 |
liver | 100% | 554.22 | 226 / 226 | 93% | 8.10 | 376 / 406 |
adrenal gland | 100% | 1127.64 | 258 / 258 | 92% | 11.38 | 212 / 230 |
adipose | 100% | 954.11 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 15.57 | 29 / 29 |
spleen | 100% | 1101.11 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 14.50 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.10 | 1 / 1 |
blood vessel | 100% | 1073.82 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1107.88 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 770.03 | 837 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 88% | 7.96 | 70 / 80 |
peripheral blood | 82% | 769.93 | 763 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0005975 | Biological process | carbohydrate metabolic process |
GO_0006282 | Biological process | regulation of DNA repair |
GO_0009225 | Biological process | nucleotide-sugar metabolic process |
GO_0006287 | Biological process | base-excision repair, gap-filling |
GO_1990966 | Biological process | ATP generation from poly-ADP-D-ribose |
GO_0016604 | Cellular component | nuclear body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005759 | Cellular component | mitochondrial matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004649 | Molecular function | poly(ADP-ribose) glycohydrolase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PARG |
Protein name | poly(ADP-ribose) glycohydrolase (EC 3.2.1.143) Poly(ADP-ribose) glycohydrolase (EC 3.2.1.143) Poly(ADP-ribose) glycohydrolase |
Synonyms | |
Description | FUNCTION: Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose) . PARG acts both as an endo- and exoglycosidase, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers . It is however unable to cleave the ester bond between the terminal ADP-ribose and ADP-ribosylated residues, leaving proteins that are mono-ADP-ribosylated . Poly(ADP-ribose) is synthesized after DNA damage is only present transiently and is rapidly degraded by PARG . Required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress, while it is not required for recovery from transient replicative stress . Responsible for the prevalence of mono-ADP-ribosylated proteins in cells, thanks to its ability to degrade poly(ADP-ribose) without cleaving the terminal protein-ribose bond . Required for retinoid acid-dependent gene transactivation, probably by removing poly(ADP-ribose) from histone demethylase KDM4D, allowing chromatin derepression at RAR-dependent gene promoters . Involved in the synthesis of ATP in the nucleus, together with PARP1, NMNAT1 and NUDT5 . Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming . . |
Accessions | Q0MQR4 A0A087WXI6 ENST00000402038.7 [Q86W56-1] ENST00000610922.1 I1VE11 ENST00000614063.4 A0A087WX07 ENST00000616448.2 [Q86W56-1] Q6X2S8 Q86W56 |